Novel placental biomarkers in prediction of preeclampsia
A prospective study about current and novel biomarkers important in screening for preeclampsia in pregnant women at high risk of developing preeclampsia after 24 weeks gestation

Preeclampsia (PE), a world largest pregnancy disorder affecting 2-8% of women,is a major cause of life loss of pregnant women and their babies
An evidence based care for the mothers and their babies
Early screening and prompt diagnosis are key measures in improving maternal morbidity and neonatal prognosis in pregnancies complicated by preeclampsia.
Motivation and background
Great advances in prediction and diagnosis have been achieved over the last years by discovery of biomarkers, especially of placental origin and already some of them have been tested in large clinical trial and have been introduced into current clinical practice. However, the performance of these biomerkes in prediction of preeclmapsia is still far from perfection and continuous research in this field is required and it great resources will still be allocated in the future.
Main purpose
The aim of this study is to individually assess and compare the performance of the three methods of screening (FMF combined method, sFlt-1/PLGF ration and PLGF alone) in pregnant women attending our maternal-fetal medicine department after 24 weeks gestation with signs and symptoms of preeclampsia and whether inclusion of additional maternal biomarkers such as NT-proBNP or NGAL (neutrophil gelatinase-associated lipocalin) can further increase the accuracy of predicting preeclampsia.
Inclusion criteria
Singleton pregnancies after 24 weeks gestation presenting with high blood pressure above 140/90 mmHg, exacerbation of preexisting hypertension, proteinuria, epigastric pain, persistent headache, visual disturbances, edema, low platelet count, elevated liver-enzyme levels, abnormal uterine artery Doppler, intrauterine fetal growth restriction
Project Management
Assistant Prof Dr. Ciobanu Anca Marina- project director
Associate Prof Dr. Panitescu Anca Maria- Mentor
Results and dissemination
We aim to detect the best alternative in early predicition of delivering with preeclampsia and to increase the performance of the existing algorithms. By identifying a higher proportion of women who will develop preeclampsia, the clinicians will plan a closed montoring, will provide adequate care for the mother and the fetus and would allow planned delivery. All these measures will have a great impact in decreasing maternal and perinatal morbidity and mortality.
We aim to publish the results of the study in representative international journals and the project leader, but also the mentor and the host institution will gain visibility by providing solid data on a subject of great interest worldwide.
Future research
Data collection
Our comprehensive assessment of pregnant women and their fetus including history, maternal characteristics, blood pressure, blood collection, ultrasound evaluation.
Maternal serum biomarkers included in the study
- sFLT- .
- PLGF-.
- NTpro BNP-
- NGAL-.


Fetal evaluation
- Estimated fetal weight.
- Placental and fetal doppler evaluation.
- Amniotic fluid volume.
“Études has saved us thousands of hours of work and has unlocked insights we never thought possible.”
Annie Steiner
CEO, Greenprint
Watch, Read, Listen
Join 900+ subscribers
Stay in the loop with everything you need to know.